This study aimed to identify the rate and impact of vancomycin-resistant enterococcal (VRE) bacteremia in patients with acute myeloid leukemia (AML) receiving induction chemotherapy (IC). Thirty-seven (10.6%) of 350 patients had VRE bacteremia during IC, with increasing rates of VRE bacteremia over the course of the study period. The overall complete remission (CR) rate for the cohort was 73%, and there was no difference in CR rate between the VRE bacteremia and non-VRE bacteremia cohorts (70% vs. 73%, p = 0.70). Unadjusted median overall survival (OS) was 12.8 months, and differed significantly between those with and without VRE bacteremia (7.1 months vs. 13.1 months, respectively; p = 0.03). The presence of VRE bacteremia during IC for AML was independently associated with increased all-cause mortality (hazard ratio 1.72, 95% confidence interval 1.13-2.63, p = 0.01).

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.1003557DOI Listing

Publication Analysis

Top Keywords

vre bacteremia
24
impact vancomycin-resistant
8
vancomycin-resistant enterococcal
8
bacteremia
8
acute myeloid
8
myeloid leukemia
8
vre
6
enterococcal bacteremia
4
bacteremia outcome
4
outcome acute
4

Similar Publications

Background , once benign intestinal flora, has transformed into formidable nosocomial pathogens as a result of the accelerated emergence of antibiotic resistance represents a major global health challenge, particularly within hospital settings. has grown more prevalent in nosocomial infections, such as urinary tract infections (UTIs), surgical site infections (SSIs) and bacteremia. The potential emergence of vancomycin-resistant (VRE) strains further complicates treatment choices for multi-drug resistant (MDR) infections.

View Article and Find Full Text PDF

Background: Studies link multidrug-resistant organism (MDRO) rectal colonization to increased infection risk, data from Greece, a country with high rates of MDRO, are limited.

Methods: We assessed bloodstream infection (BSI) risk following rectal colonization by MDROs across three Greek hospitals (2019-2022).

Results: Of 4,370 inpatients, 31.

View Article and Find Full Text PDF

Background/aim: Vancomycin-resistant Enterococcus causes significant morbidity, mortality, and excess healthcare costs when compared to vancomycin-susceptible isolates. Patients with hematological malignancies, especially those who undergo hematopoietic stem cell transplantation, are at a particularly high risk for infections with vancomycin-resistant Enterococcus, with mortality ranging from 40-100%. Linezolid and daptomycin are the two most commonly used antibiotics for treatment of vancomycin-resistant enterococcal infections, however, there has been recent emergence of resistance to these drugs as well.

View Article and Find Full Text PDF

Background: One of the main risks of infection after hematopoietic stem cell transplantation (HSCT) is infection by gram-positive bacteria, including vancomycin-resistant enterococci (VRE). Based on the format of a global review and meta-analysis study, this study aims to investigate the incidence of VRE bloodstream infection (BSI) after HSCT in colonized individuals.

Methods: The keywords of the systematic search included vancomycin-resistant enterococci and HSCT.

View Article and Find Full Text PDF
Article Synopsis
  • A 62-year-old man experienced severe symptoms, including blood in urine, fever, and chills, just a day after a Rezum procedure.
  • He was diagnosed with bacteraemia caused by bacteria resistant to carbapenems and vancomycin.
  • The patient successfully received treatment with drugs like daptomycin and eravacycline, highlighting the limited information available on such infections.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!